NAD reviews prostate supplement claims
This article was originally published in The Tan Sheet
Executive Summary
The Herbal Groups Inc. discontinued its "Prostate Health Blog" when a National Advertising Division inquiry determined the blog advertised the firm's Prostalex Plus dietary supplement, but was not clearly marked as advertising, the Council of Better Business Bureaus division says Aug. 11. Although NAD determined some blog claims were supported by the firm's supporting research, others overstated results of supporting research, including that the product leads to "improvement in erectile issues and increased sex drive." Herbal Groups believed research supports its claims but agreed to comply with NAD's recommendations. NAD referred the firm to the Federal Trade Commission when it initially declined to comply (1"The Tan Sheet" May 11, 2009, In Brief)
You may also be interested in...
NAD refers prostate supplement ad to FTC, FDA
The National Advertising Division refers advertising for the prostate health supplement Prostalex Plus to the Federal Trade Commission and FDA after the marketer, Herbal Groups, declined to participate in the Better Business Bureaus' review process. NAD requested substantiation for claims that the "all-natural supplement" would "solve your urination problems, improve prostate function" and combat the natural growth of the prostate. It also was concerned that "the Prostate Health Blog" linked on the advertiser's Web site is not independently written as it appears, but is advertising. The firm submitted a study on Prostalex, but declined to participate in the review process, NAD said in a May 5 release. The watchdog group, which rarely refers advertisers to enforcement agencies, has referred six companies to regulators this year (1"The Tan Sheet" Feb. 16, 2009, p. 19)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.